While the Food and Drug Administration is still smarting over its First Amendment court losses when it comes to off-label promotion, it hasn’t gone radio silent.
To the contrary, FDA has recently issued a number of draft guidances and a Memorandum, offering its recommendations on appropriate medical product communications in different contexts, while also reminding industry that the agency will not remain if it objects to product messaging.
Register now for this one-hour complimentary webinar with AGG attorneys, Alan Minsk and Elizabeth Mulkey, as they summarize these new FDA guidances and statements, offer their own observations on where we might be headed, and provide recommendations to maximize compliance. An opportunity for Q and A will be available.
Credits: This webinar is pending CLE credit approval by the State Bar of Georgia.